

Figure S1 Enrolled and excluded study patients.




Figure S2 Area under the curve (AUC) of the survival ROC. AUC of the 10-year survival ROC curve for IBTR in CT+ cohorts (A), AUC of the 10-year survival ROC curve for DFS in CT- cohorts (B).

Table S1 Crude and actuarial results in the CT+ and CT- group

Clinical outcomes	Chemotherapy (n=1472) (%)	Non-chemotherapy (n=402) (%)
Ipsilateral breast tumor recurrence		
5-year crude results	1.3	0.7
5-year cumulative incidence of IBTR	1.3 (≤47 days) 3.3 (>47 days)	0.8 (≤69 days) 2.4 (>69 days)
Local-regional failure		
5-year crude results	1.6	0.5
5-year cumulative incidence of LRF	1.7 (≤47 days) 3.4 (>47 days)	0.8 (≤69 days) 0 (>69 days)
Disease-free survival		
5-year crude results	8.7	3
5-year cumulative incidence of disease recurrence	10.6 (≤47 days) 13.4 (>47 days)	3.0 (≤69 days) 12.6 (>69 days)
Overall survival		
5-year crude results	1.3	0.7
5-year cumulative incidence of death	1.7 (≤47 days) 1.9 (>47 days)	0.7 (≤69 days) 2.6 (>69 days)

IBTR, ipsilateral breast tumor recurrence; LRF, local-regional failure.

Table S2 Univariate and multivariate analysis for IBTR in the CT+ group

Variable	Univariate			Multivariate		
	HR	95% CI	P	HR	95% CI	P
Age						
≤40	1			1		
>40	0.504	0.237-1.071	0.075	0.387	0.179-0.836	0.016
Interval (days)						
≤47	1					
>47	2.795	1.181-6.611	0.019	-	-	0.076
Tumor size (cm)						
≤2	1					
>2	1.590	0.728-3.473	0.245	-	-	0.326
Lymph node						
Negative	1					
Positive	0.773	0.338-1.766	0.773	-	-	0.743
Her2 status						
Negative	1			1		
Positive	5.478	2.565-11.697	0.000	4.984	2.297-10.814	0.000
Margin (first section)						
Negative	1					
Positive	0.049	0.000-236,174.251	0.701	-	-	0.473
Endocrine therapy						
No	1					
Yes	0.201	0.090-0.448	0.000	-	-	0.465
Menopause status						
Postmenopausal	1					
Premenopausal	1.689	0.639-4.460	0.290	-	-	0.340
Hormone receptor						
Negative	1			1		
Positive	0.190	0.087-0.415	0.000	0.221	0.100-0.487	0.000

IBTR, ipsilateral breast tumor recurrence; HR, hazard ratio; HER2, human epidermal growth factor receptor 2; CI, confidence interval.